Note: Upacicalcet is an investigational product candidate in the United States and subject to regulatory review and approval by the U.S. Food and Drug Administration (FDA).
Oversubscribed Financing Paves Path to NDA Submission and Pre-commercialization Efforts for upacicalcet RESEARCH TRIANGLE PARK, NC – August 20, 2024 – Pathalys Pharma, Inc., a
RESEARCH TRIANGLE PARK, NC — August 13, 2024 – Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney
Pathalys and LaunchTx leverage recently announced collaboration to accelerate enrollment for the upacicalcet development program. Research Triangle Park, North Carolina and Boston, Massachusetts, May 31, 2023 – Pathalys Pharma,
Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ: CG), led financings and was joined by Carlyle, OrbiMed,
RESEARCH TRIANGLE PARK, N.C., June 2, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range…
Research Triangle Park, N.C., April 8, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range
– Plans for Phase 3 Program Presented at National Kidney Foundation’s Annual Spring Clinical Meeting – Research Triangle Park, N.C., April 7, 2022 – Pathalys
– Executive Leadership Team Brings Diverse Skills and Broad Expertise to New Venture – RESEARCH TRIANGLE PARK, N.C., March 30, 2022 – Pathalys Pharma, Inc.,
– Company Acquires License to EA Pharma’s Upacicalcet Worldwide Outside of Japan and Asia – Industry Veteran Neal Fowler Named Chief Executive Officer…
SANWA KAGAKU KENKYUSHO Co., Ltd. (Head Office: Nagoya, President and CEO: Shusaku Isono, Suzuken Group, ; “SANWA KAGAKU”) will launch UPASITA® IV…
—
Source: Kessei
SANWA KAGAKU KENKYUSHO Co., Ltd. (Head Office: Nagoya, President and CEO : Shusaku Isono, Suzuken Group, ; “SANWA KAGAKU”) has received Marketing…
—
Source: Kissei
Upacicalcet, a novel intravenous small molecule calcimimetic in late-stage development in Japan, may help control intact parathyroid hormone (iPTH) levels in patients with secondary hyperparathyroidism (SHPT)…
—
Source: Renal & Urology News
Calcimimetics are widely used for the treatment of secondary hyperparathyroidism (SHPT) in chronic renal failure patients. However, there are some problems with calcimimetics treatment…
—
Source: American Society of Nephrology – Kidney Week 2020